We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vascular Function and Uterine Fibroids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02123069
Recruitment Status : Completed
First Posted : April 25, 2014
Last Update Posted : March 2, 2018
Sponsor:
Information provided by (Responsible Party):
Michael J. Joyner, M.D., Mayo Clinic

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to learn how uterine fibroids may be connected to heart disease and high blood pressure. It is not known what causes fibroids, but they frequently occur in women who also have high blood pressure, heart disease, and stroke. The investigators of this study want to learn if certain changes in the blood vessels or nerve activity can put women at risk for these diseases and for fibroids.

Condition or disease Intervention/treatment
Leiomyoma Device: Brachial artery catheter Drug: Acetylcholine Drug: Nitroprusside Drug: Norepinephrine Drug: Nitroprusside and phenylephrine

Detailed Description:

The investigators are inviting women, 25-50 years old, who have not gone through menopause to participate in this study. The investigators are looking for some women with uterine fibroids and some without uterine fibroids based on ultrasound or MRI. If the patients have not had a recent ultrasound or MRI of the uterus, a physician can provide one.

Individuals cannot participate if they have high blood pressure, diabetes, or disease in the kidneys, lungs, or blood vessels. Also, individuals who smoke, have high cholesterol, or are obese (BMI is higher than 30) cannot participate. Certain medications, including high blood pressure medications, beta-blockers and anti-depressants, will also limit potential patient participation. The investigators would be happy to review medications for potential participants.

Screen Day:

One of the members of the research team will review the study and the informed consent document with the patient. The patient will have their height, weight, blood pressure, pulse and respirations measured. The patient will also complete three questionnaires. If the patient has not had an ultrasound of the uterus in the last 12 months, a physician will complete one for her.

Study Day:

The patient will need to fast overnight (no eating or drinking). The investigators will draw a blood sample and then do a series of tests on the participant's blood vessels. For some of the tests, medication will be given through an IV. The investigators will also test nerve activity in the nerve on the outer aspect of the leg.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 28 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Sympathetic Nerve Activity and Vascular Function in Women With Uterine Leiomyomata
Study Start Date : April 2013
Actual Primary Completion Date : March 1, 2018
Actual Study Completion Date : March 1, 2018
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Women with uterine fibroids
  • Brachial artery catheter
  • Acetylcholine
  • Nitroprusside
  • Norepinephrine
  • Nitroprusside and phenylephrine
 Device: Brachial artery catheter
A catheter will be placed in the brachial artery by a physician on the study day.

Drug: Acetylcholine
Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.

Drug: Nitroprusside
Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.

Drug: Norepinephrine
Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.

Drug: Nitroprusside and phenylephrine
A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
Women without uterine fibroids
  • Brachial artery catheter
  • Acetylcholine
  • Nitroprusside
  • Norepinephrine
  • Nitroprusside and phenylephrine
 Device: Brachial artery catheter
A catheter will be placed in the brachial artery by a physician on the study day.

Drug: Acetylcholine
Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.

Drug: Nitroprusside
Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.

Drug: Norepinephrine
Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.

Drug: Nitroprusside and phenylephrine
A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Baseline systolic, diastolic, and mean blood pressures [ Time Frame: One day (study day) ]
  2. Baseline sympathetic nerve activity [ Time Frame: One day (study day) ]
    Nerve "burst" activity will be measured across 10 minutes.


Secondary Outcome Measures :
  1. Changes in forearm blood flow levels in response to acetylcholine infusion [ Time Frame: One day (study day) ]
  2. Changes in forearm blood flow levels in response to nitroprusside infusion [ Time Frame: One day (study day) ]
  3. Changes in forearm blood flow levels in response to norepinephrine infusion [ Time Frame: One day (study day) ]
  4. Change in blood pressure in response to infusions of nitroprusside and phenylephrine [ Time Frame: One day (study) ]
    An infusion of nitroprusside will be given, followed by an infusion of phenylephrine one minute later.

  5. Pulse wave velocity (an index of vessel stiffness) [ Time Frame: One day (study day) ]

Other Outcome Measures:
  1. Female sex hormone levels [ Time Frame: One day (study day) ]
    Blood samples will be collected to measure levels of estrogen and progesterone.


Biospecimen Retention:   Samples With DNA

Whole blood and serum

No DNA extraction from samples is planned.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Premenopausal women, ages 25-50 years old, who have and have not been diagnosed with uterine fibroids. Women will be recruited from Rochester, Minnesota and the surrounding area (including locations in Iowa and Wisconsin). Women eligible to participate will be in good health and not taking medications.
Criteria

Inclusion Criteria:

  • Women 25-50 years old
  • Premenopausal

Exclusion Criteria:

  • Postmenopausal
  • Pregnant or currently breastfeeding
  • Using blood pressure medications or anti-depression medications
  • High blood pressure
  • Diabetes
  • Disease in the kidneys, lungs, or blood vessels
  • Chronic diseases (for example: Crohn's disease, rheumatoid arthritis, bipolar mood disorder, etc.)
  • Smoker
  • High cholesterol
  • BMI higher than 30
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02123069


Locations
Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Layout table for investigator information
Principal Investigator: Michael J Joyner, M.D. Mayo Clinic
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Michael J. Joyner, M.D., PI, Mayo Clinic
ClinicalTrials.gov Identifier: NCT02123069    
Other Study ID Numbers: 13-000596
First Posted: April 25, 2014    Key Record Dates
Last Update Posted: March 2, 2018
Last Verified: March 2018
Keywords provided by Michael J. Joyner, M.D., Mayo Clinic:
Autonomic nervous system
Blood pressure
Blood vessels
Physiological effects of drugs
Vascular stiffness
Additional relevant MeSH terms:
Layout table for MeSH terms
Leiomyoma
Myofibroma
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Connective Tissue
Connective Tissue Diseases
Nitroprusside
Phenylephrine
Oxymetazoline
Norepinephrine
Acetylcholine
Cardiotonic Agents
Mydriatics
 Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sympathomimetics
Vasoconstrictor Agents
Nasal Decongestants
Respiratory System Agents
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Antihypertensive Agents